ENZN

Enzon Pharmaceuticals, Inc. [ENZN] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ENZN Stock Summary

In the News

08:30 28 Mar 2024 ENZN

7 Undervalued Biotech Stocks to Buy Before They Boom

You'll often hear people say that bear markets are great for finding bargains, and that's true. With the exception of energy, every major sector is in the red for the year.

08:55 28 Mar 2024 ENZN

Enzon Pharmaceuticals, Inc. CEO Andrew Rackear to Retire; Richard L. Feinstein, Enzon's CFO, to Assume Position of CEO and Remain CFO

CRANFORD, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTC:ENZN) announced today that Andrew Rackear has communicated to the Board his intent to retire from his role as the Company's Chief Executive Officer effective February 26, 2021. Andy joined Enzon in 2010 as Vice-President and General Counsel and has served as CEO since 2016. Upon Andy's retirement, Richard L. Feinstein, Enzon's Chief Financial Officer, will also assume the role of Chief Executive Officer and Secretary, as well as remain the Company's Chief Financial Officer. Mr. Rackear will be available as a consultant to the Company following his retirement, as may be needed.

ENZN Financial details

Company Rating
Strong Buy
Market Cap
5.2M
Income
1.37M
Revenue
0
Book val./share
0.62
Cash/share
0.63
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
7.27
Forward P/E
-
PEG
-0.48
P/S
289.15
P/B
2.99
P/C
0.15
P/FCF
7.67
Quick Ratio
114.67
Current Ratio
115.48
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0
EPS next Y
-
EPS next Q
-
EPS this Y
-840%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-575%
-
-
-
-
SMA20
-
SMA50
-20%
SMA100
-38.46%
Inst Own
0.02%
Inst Trans
1.05%
ROA
2%
ROE
3%
ROC
-0.02%
Gross Margin
100%
Oper. Margin
-3996%
Profit Margin
3977%
Payout
123%
Shs Outstand
74.21M
Shs Float
66.17M
-
-
-
-
Target Price
-
52W Range
0.06-0.27
52W High
-
52W Low
-
RSI
56.72
Rel Volume
0.01
Avg Volume
23.1K
Volume
147
Perf Week
14.13%
Perf Month
5.59%
Perf Quarter
-36.16%
Perf Half Y
-32.93%
-
-
-
-
Beta
0.273
-
-
Volatility
0.01%, 0.01%
Prev Close
11.83%
Price
0.0945
Change
51.93%

ENZN Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
000.0100
Net income per share
-0.02-0.03-0.0100.02
Operating cash flow per share
0.16-0.01-0.01-0.010.02
Free cash flow per share
0.16-0.01-0.01-0.010.02
Cash per share
0.120.940.640.630.63
Book value per share
0.140.940.640.620.62
Tangible book value per share
0.140.940.640.620.62
Share holders equity per share
0.140.940.640.620.62
Interest debt per share
000-0.010
Market cap
9.11M12.69M25.42M18.31M6.94M
Enterprise value
3.66M-35.45M-22.22M-28.68M-40.07M
P/E ratio
-9.3-9.68-54.2-98.415.06
Price to sales ratio
44244.136.26704.040
POCF ratio
1.32-33.4-50.74-27.785.32
PFCF ratio
1.32-33.4-50.74-27.785.32
P/B Ratio
1.50.270.540.40.15
PTB ratio
1.50.270.540.40.15
EV to sales
17.69-681.71-31.7-1.1K0
Enterprise value over EBITDA
-3.7627.1647.3827.7938.38
EV to operating cash flow
0.5393.2944.3643.52-30.7
EV to free cash flow
0.5393.2944.3643.52-30.7
Earnings yield
-0.11-0.1-0.02-0.010.2
Free cash flow yield
0.76-0.03-0.02-0.040.19
Debt to equity
00000
Debt to assets
00000
Net debt to EBITDA
5.636.89101.5845.5345.03
Current ratio
14.17117.07118.527.8927.62
Interest coverage
0001.60
Income quality
-7.050.291.073.540.95
Dividend Yield
0.870.040.080.070.18
Payout ratio
-8.13-0.35-4.31-6.850.93
Sales general and administrative to revenue
5.726.11.6740.690
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
00000
Graham number
0.260.730.30.190.51
ROIC
-0.16-0.03-0.01-0.01-0.03
Return on tangible assets
-0.15-0.03-0.0100.03
Graham Net
0.120.930.640.610.61
Working capital
5.57M47.82M47.35M45.69M45.63M
Tangible asset value
6.06M47.82M47.35M45.89M45.99M
Net current asset value
5.57M47.82M47.35M45.69M45.63M
Invested capital
00000
Average receivables
4.23M258K29.5K14K0
Average payables
381.5K313K316.5K331K331K
Average inventory
00000
Days sales outstanding
855.19217.614.5800
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
0.431.6825.0400
Payables turnover
00000
Inventory turnover
00000
ROE
-0.16-0.03-0.0100.03
Capex per share
00000

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
00000.01
Operating cash flow per share
0000.010.01
Free cash flow per share
0000.010.01
Cash per share
0.630.620.620.630.63
Book value per share
0.620.620.620.030.62
Tangible book value per share
0.620.620.620.030.62
Share holders equity per share
0.620.620.620.030.62
Interest debt per share
0-0.01000
Market cap
18.31M19.3M14.84M10.89M6.94M
Enterprise value
-28.68M-26.58M-31.29M-35.67M-40.07M
P/E ratio
13.7424.4920.288.482.58
Price to sales ratio
704.040000
POCF ratio
140.81113.5158.4425.5515.26
PFCF ratio
140.81113.5158.4425.5515.26
P/B Ratio
0.40.420.324.330.15
PTB ratio
0.40.420.324.330.15
EV to sales
-1.1K0000
Enterprise value over EBITDA
135.9193.2798.39158.54185.51
EV to operating cash flow
-220.59-156.36-123.18-83.74-88.06
EV to free cash flow
-220.59-156.36-123.18-83.74-88.06
Earnings yield
0.020.010.010.030.1
Free cash flow yield
0.010.010.020.040.07
Debt to equity
00000
Debt to assets
00000
Net debt to EBITDA
222.66160.97145.07206.92217.65
Current ratio
27.89113.38115.63115.4827.62
Interest coverage
0.610.64000
Income quality
0.390.861.391.330.68
Dividend Yield
00.07000
Payout ratio
06.47000
Sales general and administrative to revenue
9.120000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
00000
Graham number
0.250.190.190.060.36
ROIC
-0.01-0.01-0.01-0.07-0.01
Return on tangible assets
0.01000.010.01
Graham Net
0.610.610.620.030.61
Working capital
45.69M45.85M46.08M46.48M45.63M
Tangible asset value
45.89M46.09M46.27M2.52M45.99M
Net current asset value
45.69M45.85M46.08M2.4M45.63M
Invested capital
00000
Average receivables
00000
Average payables
331K331K331K334K334K
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
0.01000.130.01
Capex per share
00000

ENZN Frequently Asked Questions

What is Enzon Pharmaceuticals, Inc. stock symbol ?

Enzon Pharmaceuticals, Inc. is a US stock , located in Cranford of Nj and trading under the symbol ENZN

What is Enzon Pharmaceuticals, Inc. stock quote today ?

Enzon Pharmaceuticals, Inc. stock price is $0.0945 today.

Is Enzon Pharmaceuticals, Inc. stock public?

Yes, Enzon Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Same Price Range
Similar Market Cap